News - Mergers & Acquisitions, Oncology, Biotechnology

1 to 25 of 44 results

BioAlliance and Topotarget progress merger plan

BioAlliance and Topotarget progress merger plan

01-07-2014

France-base BioAlliance Pharma and Denmark’s Topotarget say that the shareholders of both companies…

BioAlliance PharmaBiotechnologyMergers & AcquisitionsOncologyOnxeoTopotarget

Definitive merger plan between BioAlliance Pharma and Topotarget

Definitive merger plan between BioAlliance Pharma and Topotarget

22-05-2014

French orphan drug developer BioAlliance Pharma and Denmark’s Topotarget have confirmed details of…

BioAlliance PharmaBiotechnologyMergers & AcquisitionsOncologyOnxeoTopotarget

NeoStem to acquire California Stem Cell, expanding pipeline

14-04-2014

USA-based NeoStem has entered into a definitive agreement to acquire California Stem Cell, an Irvine,…

BiotechnologyCalifornia Stem Cellmelapuldencel-TMergers & AcquisitionsNeoStemOncologyResearch

Roche in deal with Oryzon to develop epigenetics-based medicines; Buys IQuum

Roche in deal with Oryzon to develop epigenetics-based medicines; Buys IQuum

07-04-2014

Swiss drug major Roche has entered to a worldwide collaboration with Spanish functional genomics firm…

BiotechnologyIQuumLicensingMergers & AcquisitionsOncologyORY-1001Oryzon GenomicsRoche

Tiziana Pharma plans listing via reverse takeover

Tiziana Pharma plans listing via reverse takeover

31-03-2014

Tiziana Pharma, a recently-established UK biotech company that has licensed technology for a potential…

BiotechnologyMergers & AcquisitionsOncologyTiziana

Verastem acquires cancer stem cell inhibitor VS-4718 rights from Poniard

27-02-2014

US drug developer Verastem has acquired the license to VS-4718, which targets cancer stem cells, held…

BiotechnologyMergers & AcquisitionsOncologyPoniard PharmaceuticalsVerastemVS-4718

Novartis to acquire CoStim, expanding cancer immunotherapy research program

Novartis to acquire CoStim, expanding cancer immunotherapy research program

17-02-2014

Swiss drug major Novartis said this morning that it is broadening its cancer immunotherapy research program…

BiotechnologyCoStim PharmaceuticalsMergers & AcquisitionsNovartisOncology

Agenus to acquire Switzerland’s 4-Antibody AG

14-01-2014

US biotech firm Agenus has entered into a definitive agreement to acquire 4-Antibody AG, a private Switzerland-headquartered…

4-Antibody AGAgenusBiotechnologyGITRMergers & AcquisitionsOncologyOX40

Walvax Biotech to take 64% stake in Genor BioPharma for around $49 million

Walvax Biotech to take 64% stake in Genor BioPharma for around $49 million

31-12-2013

China’s Walvax Biotech has revealed it plans to acquire a controlling 64% equity stake in Shanghai’s…

Asia-PacificBiosimilarsBiotechnologyChinaMergers & AcquisitionsOncology

Senesco enters merger accord with Fabrus

31-12-2013

USA-based biotech firm Senesco Technologies has agreed to terms and executed a non-binding Letter of…

BiotechnologyFabrusMergers & AcquisitionsOncologySenesco Technologies

Advaxis rockets on out-licensing ADXS-HPV in Asia

09-12-2013

Shares of US cancer drug developer Advaxis leapt 22% to $4.38 in pre-market trading as the company revealed…

AdvaxisADXS-HPVBiotechnologyGlobal BioPharmaLicensingMergers & AcquisitionsOncologyTaiwan Biotech

OncoMed rockets on possible multi-billion dollar deal with Celgene

OncoMed rockets on possible multi-billion dollar deal with Celgene

04-12-2013

US biotech companies OncoMed Pharmaceuticals and Celgene have entered an agreement to jointly develop…

Anti-DLL4BiotechnologyCelgenedemcizumabLicensingMergers & AcquisitionsOMP-21M18OncologyOncoMed PharmaceuticalsResearch

Korea’s SillaJen to acquire Jennerex in up to $150 million deal

Korea’s SillaJen to acquire Jennerex in up to $150 million deal

27-11-2013

Privately-held South Korean firm SillaJen says it has executed a definitive merger agreement to acquire…

BiotechnologyJennerexMergers & AcquisitionsOncologyPexa-VecSillaJenTransgene

Clovis Oncology buys Italian firm for $200 million

21-11-2013

US biotech firm Clovis Oncology says it has acquired EOS (Ethical Oncology Science), a privately-held…

BiotechnologyClovis OncologylucitanibMergers & AcquisitionsOncologyServier

PharmAkea, Celgene and Bay City Capital collaborate on cancer and fibrotic disease

PharmAkea, Celgene and Bay City Capital collaborate on cancer and fibrotic disease

09-10-2013

PharmAkea Therapeutics and Bay City Capital have entered a strategic collaboration with Celgene designed…

BiotechnologyCelgeneMergers & AcquisitionsNorth AmericaOncologyPharmAkeaResearch

Otsuka confirms takeover bid for Astex Pharmaceuticals for $886 million

05-09-2013

Following heavy speculation on Wednesday (see The Pharma Letter story earlier today), this morning Japanese…

Astex PharmaceuticalsBiotechnologyMergers & AcquisitionsOncologyOtsukaPharmaceutical

Otsuka said to be buying Astex Pharma

05-09-2013

Japanese mid-size drugmaker Otsuka (TYO: 4768) is planning to acquire USA-based Astex Pharmaceuticals…

Astex PharmaceuticalsBiotechnologyMergers & AcquisitionsOncologyOtsukaPharmaceutical

Onyx Pharma accepts increased bid from Amgen

27-08-2013

Amgen (Nasdaq: AMGN), the world largest independent biotech group, said on Sunday (August 25) that the…

AmgenBayerBiotechnologyKyprolisMergers & AcquisitionsOncologyOnyx PharmaceuticalsPfizer

AstraZeneca nabs Amplimmune for $500 million

27-08-2013

In a further bid to expand its ailing research portfolio, Anglo-Swedish drug major AstraZeneca (LSE:…

AmplimmuneAstraZenecaBiotechnologyMergers & AcquisitionsOncologyPharmaceutical

Acetylon snags $100 million upfront cash and acquisition option

30-07-2013

Privately-held Acetylon and US biotech firm Celgene (Nasdaq: CELG) have entered into an exclusive strategic…

Acetylon PharmaceuticalsBiotechnologyCelgeneLicensingMergers & AcquisitionsNeurologicalOncology

Genesis Biopharma completes merger with Lion Biotech

26-07-2013

US biotech firm Genesis Biopharma (OTC Bulletin Board: GNBP) says that it has completed a merger with…

BiotechnologyGenesis BiopharmaLion BiotechnologiesMergers & AcquisitionsOncology

Bayer and Onyx file for EU and US approval for expanded use of Nexavar; completes Steigerwald buy

01-07-2013

German drug major Bayer (BAYN: DE) and US partner Onyx Pharmaceuticals (Nasdaq: ONXX) have filed for…

BayerBiotechnologyEuropeMergers & AcquisitionsNexavarNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulationSteigerwald

Onyx Pharma rejects Amgen's unsolicited $120 per share takeover offer

01-07-2013

Following a day of speculation and rumor on Friday, US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX)…

AmgenBayerBiotechnologyCelgeneMergers & AcquisitionsOncologyOnyx PharmaceuticalsPfizerRoche

MorphoSys and Celgene in deal to advance MOR202 for multiple myeloma

27-06-2013

German biotech firm MorphoSys (FSE: MOR) and USA-based Celgene (Nasdaq: CELG), the world's largest independent…

BiotechnologyCelgeneEuropeLicensingMergers & AcquisitionsMOR202MorphoSysOncology

1 to 25 of 44 results

Back to top